PharVision Advisers LLC Acquires New Holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC)

PharVision Advisers LLC bought a new position in Alphatec Holdings, Inc. (NASDAQ:ATEC) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 21,895 shares of the medical technology company’s stock, valued at approximately $201,000.

Other hedge funds also recently bought and sold shares of the company. R Squared Ltd bought a new position in shares of Alphatec during the 4th quarter valued at about $29,000. Comerica Bank lifted its stake in Alphatec by 66.8% in the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock valued at $29,000 after buying an additional 1,248 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Alphatec by 973.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock valued at $43,000 after buying an additional 4,234 shares during the period. Quarry LP boosted its holdings in shares of Alphatec by 79.2% in the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company’s stock valued at $49,000 after buying an additional 2,375 shares during the period. Finally, Newton One Investments LLC bought a new stake in shares of Alphatec during the fourth quarter worth $50,000. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Alphatec Price Performance

NASDAQ:ATEC opened at $12.45 on Friday. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $13.14. The company has a market cap of $1.82 billion, a P/E ratio of -9.73 and a beta of 1.06. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The stock’s 50-day simple moving average is $11.06 and its 200 day simple moving average is $10.53.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.23). The company had revenue of $169.18 million for the quarter, compared to analyst estimates of $167.57 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The firm’s revenue for the quarter was up 22.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.34) EPS. As a group, sell-side analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on ATEC. Piper Sandler reaffirmed an “overweight” rating and issued a $15.00 price objective (up from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a report on Monday, April 14th. Wall Street Zen upgraded Alphatec from a “sell” rating to a “hold” rating in a report on Friday, February 28th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $16.00 target price on shares of Alphatec in a research report on Friday, May 2nd. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $17.89.

Insider Buying and Selling

In related news, EVP David Sponsel sold 12,946 shares of Alphatec stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $10.73, for a total transaction of $138,910.58. Following the completion of the transaction, the executive vice president now owns 722,128 shares in the company, valued at approximately $7,748,433.44. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Patrick Miles sold 12,691 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $10.64, for a total value of $135,032.24. Following the transaction, the chief executive officer now directly owns 5,857,603 shares in the company, valued at approximately $62,324,895.92. This trade represents a 0.22% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 182,320 shares of company stock worth $2,136,227. Insiders own 22.80% of the company’s stock.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.